GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pulse Biosciences PLSE · USD

Health Care · US listing · 🇺🇸 United States

Compare

58.17

+9.16%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$350,000

FY2016FY2025

Net income

−$72.8m

FY2016FY2025

Free cash flow

−$54.4m

FY2016FY2025

Shareholders' equity

$80.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$350,000—−$9,000$700,000$1.4m$114,000——$247,000$68,000
Gross profit−$1.3m−$1.2m−$1.2m−$11.2m−$550,000−$1.1m−$666,000−$665,000−$665,000−$665,000
Research and development$44.7m$32.3m$27.8m$20.8m$28.6m$26.4m$25.0m$17.3m$9.6m$6.0m
Operating income−$76.9m−$56.3m−$43.6m−$58.1m−$63.0m−$50.0m−$48.0m−$38.0m−$25.8m−$9.6m
Net income−$72.8m−$53.6m−$42.2m−$59.0m−$63.2m−$49.7m−$46.0m−$37.5m−$25.6m−$9.5m
Diluted earnings per share-1.08-0.92-0.77-1.58-2.13-1.96-2.22-2.13-1.54-0.71

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$96.1m$132.5m$59.2m$77.9m$54.2m$41.3m$41.9m$70.6m$49.8m$26.3m
Cash and short-term investments$80.7m$118.0m$44.4m$61.1m$28.6m$20.5m$25.4m$59.6m$38.1m$16.4m
Total liabilities$15.5m$17.6m$14.8m$80.1m$18.6m$18.4m$11.2m$4.3m$3.8m$1.0m
Debt$1.6m——$65.9m$440,000—————
Shareholders' equity$80.7m$114.9m$44.4m−$2.2m$35.7m$22.9m$30.7m$66.3m$46.0m$25.3m
Shares outstanding67m58m55m37m30m25m21m18m17m13m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$54.1m−$36.3m−$33.0m−$47.0m−$54.1m−$35.4m−$34.2m−$23.9m−$11.1m−$8.1m
Capital spending−$315,000−$125,000−$121,000−$401,000−$437,000−$441,000−$608,000−$276,000−$2.6m−$64,000
Free cash flow−$54.4m−$36.5m−$33.2m−$47.4m−$54.5m−$35.8m−$34.8m−$24.2m−$13.6m−$8.1m
Dividends paid————−$810,000—−$619,000———

Financial ratios

Data as of 2 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2017
Gross margin-360.0%—13411.1%-1606.3%-38.8%-960.5%-269.2%
Operating margin-20794.6%—456777.8%-8293.9%-4443.9%-43828.9%-10351.0%
Net margin-20794.6%—469000.0%-8421.9%-4454.2%-43628.9%-10351.0%
Return on equity-90.2%-46.7%-95.2%2622.5%-177.0%-217.2%—
Return on assets-75.7%-40.5%-71.4%-75.7%-116.4%-120.4%—
Free cash flow yield-1.5%-1.2%-1.1%-2.4%-3.5%-2.6%—
Revenue growth——-101.3%-50.6%1143.9%—263.2%
Earnings growth35.8%26.9%-28.4%-6.7%27.0%8.2%—
Current ratio10.53x11.88x6.76x10.39x4.30x2.95x—
Debt to equity0.02x0.01x0.02x-29.72x0.03x0.02x—
Equity ratio83.9%86.7%75.0%-2.9%65.8%55.4%—
Interest coverage——-37.37x-129.59x-97.54x——
R&D as a share of sales12777.4%—-308855.6%2977.0%2019.7%23196.5%3905.3%
Buybacks as a share of market value-15.4%-6.1%-47.9%-25.6%-16.9%-22.2%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-20.6%25.2%—
Operating income9.8%9.0%32.9%
Net income7.3%7.9%38.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-12.7-19.0-16.0-1.8-7.0-12.2-6.0-5.4-15.3-9.1
Price to sales——-74878.9147.3309.5—————

Market value over time

30 Nov 2016 to 30 Oct 2026, in USD

$81.6m$3.62bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-19%44%359%-83%-30%69%33%-57%322%32%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.